Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 584 participants.

Also called NCT06291376

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 584 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06291376
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Czechia, France, Germany, Greece, Hong Kong SAR China, Israel, Italy, Japan, Malaysia, Netherlands, Poland, Saudi Arabia, Slovakia, South Korea, Spain, Taiwan, Thailand, Türkiye, United Kingdom (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT06291376. Randomized; quadruple masking; primary purpose treatment. Start 2024-03-29 (actual); primary completion 2026-01-05 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
Acronym
I CAN
Condition
Immunoglobulin A Nephropathy
Condition
IgAN
Intervention (Drug)
Ravulizumab
Intervention (Drug)
Placebo
Lead sponsor
Alexion Pharmaceuticals, Inc. (class: industry)

Record details

Record id
cardio:ct-nct06291376
Content hash
e3ec158a0d356f936d604bbedf77ccc255e6f1de47199e2499e0cbb0f0718cd8